The U.S. Food and Drug Administration granted broader clearance for GSK’s respiratory syncytial virus vaccine Arexvy, extending the labeled population and potential use cases for the shot. The expanded clearance updates GSK’s regulatory position after an initial launch that saw strong early uptake but subsequent sales plateauing. GSK said the decision could support wider adoption by clinicians and payors; company statements noted the label change followed additional safety and effectiveness data submitted to regulators. The expansion arrives amid a competitive adult‑vaccine market and ongoing scrutiny of vaccine performance against seasonal respiratory threats.